{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:40:01Z","timestamp":1782351601352,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T00:00:00Z","timestamp":1484352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CONACYT-TUBITAK","award":["265991"],"award-info":[{"award-number":["265991"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s12640-016-9698-1","type":"journal-article","created":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T02:55:19Z","timestamp":1484362519000},"page":"532-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors"],"prefix":"10.1007","volume":"31","author":[{"given":"Angel","family":"Escamilla-Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Palencia-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Col\u00edn-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Galv\u00e1n-Arzate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"T\u00fanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,14]]},"reference":[{"key":"9698_CR1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brainres.2004.11.040","volume":"1033","author":"JA Aguirre","year":"2005","unstructured":"Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, Fuxe K (2005) Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 1033:216\u2013220","journal-title":"Brain Res"},{"key":"9698_CR2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.chembiol.2005.08.011","volume":"12","author":"JP Alexander","year":"2005","unstructured":"Alexander JP, Cravatt BF (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179\u20131187","journal-title":"Chem Biol"},{"key":"9698_CR3","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80:4546\u20134550","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9698_CR4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0076-6879(78)52032-6","volume":"52","author":"JA Buege","year":"1978","unstructured":"Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302\u2013310","journal-title":"Methods Enzymol"},{"key":"9698_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","volume":"246","author":"RE Burke","year":"2013","unstructured":"Burke RE, O\u2019Malley K (2013) Axon degeneration in Parkinson\u2019s disease. Exp Neurol 246:72\u201383","journal-title":"Exp Neurol"},{"key":"9698_CR6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.bjp.0707584","volume":"153","author":"GA Cabral","year":"2008","unstructured":"Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240\u2013251","journal-title":"Br J Pharmacol"},{"key":"9698_CR7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbi.2016.06.010","volume":"57","author":"M Celorrio","year":"2016","unstructured":"Celorrio M, Fern\u00e1ndez-Su\u00e1rez D, Rojo-Bustamante E, Echeverry-Alzate V, Ram\u00edrez MJ, Hillard CJ, L\u00f3pez-Moreno JA, Maldonado R, Oyarz\u00e1bal J, Franco R, Aymerich MS (2016) Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson\u2019s disease. Brain Behav Immun 57:94\u2013105","journal-title":"Brain Behav Immun"},{"key":"9698_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuroscience.2012.11.031","volume":"231","author":"AL Colin-Gonzalez","year":"2013","unstructured":"Colin-Gonzalez AL, Orozco-Ibarra M, Chanez-Cardenas ME, Rangel-Lopez E, Santamaria A, Pedraza-Chaverri J, Barrera-Oviedo D, Maldonado PD (2013) Heme oxygenase-1 (HO-1) upregulation delays morphological and oxidative damage induced in an excitotoxic\/pro-oxidant model in the rat striatum. Neuroscience 231:91\u2013101","journal-title":"Neuroscience"},{"key":"9698_CR9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/0006-291X(85)91071-X","volume":"128","author":"K Chiba","year":"1985","unstructured":"Chiba K, Trevor AJ, Castagnoli N Jr (1985) Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128:1228\u20131232","journal-title":"Biochem Biophys Res Commun"},{"key":"9698_CR10","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","volume":"187","author":"YC Chung","year":"2011","unstructured":"Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, Kim YS, Maeng S, Park SH, Jin BK (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187:6508\u20136517","journal-title":"J Immunol"},{"key":"9698_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nn.2720","volume":"14","author":"V Di Marzo","year":"2011","unstructured":"Di Marzo V (2011) Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nature Neurosci 14:9\u201315","journal-title":"Nature Neurosci"},{"key":"9698_CR12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1098\/rstb.2000.0787","volume":"356","author":"MR Elphick","year":"2001","unstructured":"Elphick MR, Egertov\u00e1 M (2001) The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond Ser B Biol Sci 356:381\u2013408","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"9698_CR13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/BF00966824","volume":"17","author":"E Garcia","year":"1992","unstructured":"Garcia E, Rios C, Sotelo J (1992) Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice. Neurochem Res 17:979\u2013982","journal-title":"Neurochem Res"},{"key":"9698_CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/10715762.2013.857019","volume":"48","author":"E Garcia","year":"2014","unstructured":"Garcia E, Santana-Martinez R, Silva-Islas CA, Col\u00edn-Gonzalez AL, Galv\u00e1n-Arzate S, Heras Y, Maldonado PD, Sotelo J, Santamar\u00eda A (2014) S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2. Free Radic Res 48:159\u2013167","journal-title":"Free Radic Res"},{"key":"9698_CR15","doi-asserted-by":"crossref","first-page":"25.11","DOI":"10.3389\/fncel.2015.00025","volume":"9","author":"F Gardoni","year":"2015","unstructured":"Gardoni F, Bellone C (2015) Modulation of the glutamatergic transmission by dopamine: a focus on Parkinson, Huntington and addiction diseases. Front Cell Neurosci 9:25.11","journal-title":"Front Cell Neurosci"},{"key":"9698_CR16","doi-asserted-by":"crossref","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","volume":"1","author":"CG Goetz","year":"2011","unstructured":"Goetz CG (2011) The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine 1:a008862","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"9698_CR17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0891-5849(97)00206-2","volume":"24","author":"HC Hung","year":"1998","unstructured":"Hung HC, Lee EH (1998) MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radic Biol Med 24:76\u201384","journal-title":"Free Radic Biol Med"},{"key":"9698_CR18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.110.169532","volume":"336","author":"TH Johnston","year":"2011","unstructured":"Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM (2011) Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson\u2019s disease. J Pharmacol Exp Ther 336:423\u2013430","journal-title":"J Pharmacol Exp Ther"},{"key":"9698_CR19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912","journal-title":"Lancet"},{"key":"9698_CR20","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1523\/JNEUROSCI.2959-05.2005","volume":"25","author":"AC Kreitzer","year":"2005","unstructured":"Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25:10537\u201310545","journal-title":"J Neurosci"},{"key":"9698_CR21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","volume":"445","author":"AC Kreitzer","year":"2007","unstructured":"Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson\u2019s disease models. Nature 445:643\u2013647","journal-title":"Nature"},{"key":"9698_CR22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979\u2013980","journal-title":"Science"},{"key":"9698_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3940(84)90293-3","volume":"48","author":"JW Langston","year":"1984","unstructured":"Langston JW, Irwin I, Langston EB, Forno LS (1984) 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48:87\u201392","journal-title":"Neurosci Lett"},{"key":"9698_CR24","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","volume":"14","author":"I Lastres-Becker","year":"2001","unstructured":"Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fern\u00e1ndez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson\u2019s syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827\u20131832","journal-title":"Eur J Neurosci"},{"key":"9698_CR25","doi-asserted-by":"crossref","first-page":"19144","DOI":"10.1073\/pnas.0509588102","volume":"102","author":"JE Lauckner","year":"2005","unstructured":"Lauckner JE, Hille B, Mackie K (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq\/11 G proteins. Proc Natl Acad Sci U S A 102:19144\u201319149","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9698_CR26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"9698_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-6606-7-33","volume":"7","author":"J Ma","year":"2014","unstructured":"Ma J, Choi B-R, Chung C-H, Min SS, Jeon WK, Han J-S (2014) Chronic brain inflammation causes a reduction in GluN2A and GluN2B subunits of NMDA receptors and an increase in the phosphorylation of mitogen-activated protein kinases in the hippocampus. Mol Brain 7:33","journal-title":"Mol Brain"},{"key":"9698_CR28","first-page":"233","volume-title":"The unpaved road to the endogenous brain cannabinoid ligands, the anandamides in \u201cCannabinoid Receptors\u201d","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam R, Fride E (1995) In: Pertwee R (ed) The unpaved road to the endogenous brain cannabinoid ligands, the anandamides in \u201cCannabinoid Receptors\u201d. Academic Press, London, pp 233\u2013258"},{"key":"9698_CR29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0304-3940(98)00427-3","volume":"250","author":"M Mogi","year":"1998","unstructured":"Mogi M, Togari A, Ogawa M, Ikeguchi K, Shizuma N, Fan D, Nakano I, Nagatsu T (1998) Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum. Neurosci Lett 250:25\u201328","journal-title":"Neurosci Lett"},{"key":"9698_CR30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm.2722","volume":"18","author":"M Morales","year":"2012","unstructured":"Morales M, Bonci A (2012) Getting to the core of addiction: hooking CB2 receptor into drug abuse? Nat Med 18:504\u2013505","journal-title":"Nat Med"},{"key":"9698_CR31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuint.2008.10.007","volume":"54","author":"MG Morgese","year":"2009","unstructured":"Morgese MG, Cassano T, Gaetani S, Macheda T, Laconca L, Dipasquale P, Ferraro L, Antonelli T, Cuomo V, Giuffrida A (2009) Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int 54:56\u201364","journal-title":"Neurochem Int"},{"key":"9698_CR32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00702-001-0683-2","volume":"109","author":"T Obata","year":"2002","unstructured":"Obata T (2002) Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 109:1159\u20131180","journal-title":"J Neural Transm"},{"key":"9698_CR33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/0269881111400652","volume":"26","author":"ES Onaivi","year":"2012","unstructured":"Onaivi ES, Ishiguro H, Gu S, Liu QR (2012) CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 26:92\u2013103","journal-title":"J Psychopharmacol"},{"key":"9698_CR34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389\u2013462","journal-title":"Pharmacol Rev"},{"key":"9698_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","volume":"27","author":"U Pagotto","year":"2006","unstructured":"Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73\u2013100","journal-title":"Endocr Rev"},{"key":"9698_CR36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuro.2015.02.004","volume":"47","author":"G Palencia","year":"2015","unstructured":"Palencia G, Garcia E, Osorio-Rico L, Trejo-Solis C, Escamilla-Ramirez A, Sotelo J (2015) Neuroprotective effect of thalidomide on MPTP-induced toxicity. Neurotoxicology 47:82\u201387","journal-title":"Neurotoxicology"},{"key":"9698_CR37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3940(85)90229-0","volume":"60","author":"TL Perry","year":"1985","unstructured":"Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, Wall RA (1985a) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60:109\u2013114","journal-title":"Neurosci Lett"},{"key":"9698_CR38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0304-3940(85)90074-6","volume":"58","author":"TL Perry","year":"1985","unstructured":"Perry TL, Yong VW, Jones K, Wall RA, Clavier RM, Foulks JG, Wright JM (1985b) Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett 58:321\u2013326","journal-title":"Neurosci Lett"},{"key":"9698_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/3-540-26573-2_1","volume":"168","author":"RG Pertwee","year":"2005","unstructured":"Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1\u201351","journal-title":"Handb Exp Pharmacol"},{"key":"9698_CR40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","volume":"12","author":"D Piomelli","year":"2006","unstructured":"Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21\u201338","journal-title":"CNS Drug Rev"},{"key":"9698_CR41","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","volume":"29","author":"DA Price","year":"2009","unstructured":"Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong JR, Lutz B, Marsicano G, Roberts JL, Giuffrida A (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Eur J Neurosci 29:2177\u20132186","journal-title":"Eur J Neurosci"},{"key":"9698_CR42","first-page":"135","volume":"16","author":"S Przedborski","year":"2000","unstructured":"Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135\u2013142","journal-title":"Restor Neurol Neurosci"},{"key":"9698_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0304-3940(87)90543-X","volume":"75","author":"BR Ransom","year":"1987","unstructured":"Ransom BR, Kunis DM, Irwin I, Langston JW (1987) Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 75:323\u2013328","journal-title":"Neurosci Lett"},{"key":"9698_CR44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0163-7258(02)00253-X","volume":"95","author":"J Romero","year":"2002","unstructured":"Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J (2002) The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95:137\u2013152","journal-title":"Pharmacol Ther"},{"key":"9698_CR45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/jpet.107.119941","volume":"322","author":"R Russo","year":"2007","unstructured":"Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D (2007) The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3\u2032-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322:236\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"9698_CR46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fphar.2013.00169","volume":"4","author":"P S\u00e1nchez-Bl\u00e1zquez","year":"2014","unstructured":"S\u00e1nchez-Bl\u00e1zquez P, Rodr\u00edguez-Mu\u00f1\u00f3z M, Garz\u00f3n J (2014) The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 4:169","journal-title":"Front Pharmacol"},{"key":"9698_CR47","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1523\/JNEUROSCI.16-19-06125.1996","volume":"16","author":"AF Schinder","year":"1996","unstructured":"Schinder AF, Olson EC, Spitzer NC, Montal M (1996) Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16:6125\u20136133","journal-title":"J Neurosci"},{"key":"9698_CR48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/7210","volume":"2","author":"DW Self","year":"1999","unstructured":"Self DW (1999) Anandamide: a candidate neurotransmitter heads for the big leagues. Nature Neurosci 2:303\u2013304","journal-title":"Nature Neurosci"},{"key":"9698_CR49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","volume":"96","author":"V Sgambato-Faure","year":"2012","unstructured":"Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease. Prog Neurobiol 96:69\u201386","journal-title":"Prog Neurobiol"},{"key":"9698_CR50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","volume":"134","author":"RJ Smeyne","year":"2005","unstructured":"Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson\u2019s disease. Mol Brain Res 134:57\u201366","journal-title":"Mol Brain Res"},{"key":"9698_CR51","first-page":"51785","volume":"91","author":"KS Tatem","year":"2014","unstructured":"Tatem KS, Quinn JL, Phadke A, Yu Q, Gordish-Dressman H, Nagaraju K (2014) Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J Vis Exp 91:51785","journal-title":"J Vis Exp"},{"key":"9698_CR52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S1461145708009243","volume":"12","author":"YJ Yang","year":"2009","unstructured":"Yang YJ, Zhang S, Ding JH, Zhou F, Hu G (2009) Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation. Int J Neuropsychopharmacol 12:317\u2013327","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-016-9698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-016-9698-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-016-9698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T18:24:50Z","timestamp":1658427890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-016-9698-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,14]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["9698"],"URL":"https:\/\/doi.org\/10.1007\/s12640-016-9698-1","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,14]]}}}